Further studies are necessary to evaluate the therapeutic effectiveness of the combination of mIDH inhibitors with hypomethylating drugs and the inhibitors of tyrosine kinase, mTORC1, OxPHOS, GLS, Nrf2, PARP and BCL-2, in AML therapy. The gene discussed is GLS; the disease is acute myeloid leukemia.